A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study
Introduction: Psoriasis is a common skin presentation in dermatology OPD. Methotrexate and apremilast are frequently used for the management of chronic plaque psoriasis. Objectives: To compare the efficacy and safety of methotrexate versus apremilast for the management of chronic plaque psori...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON)
2024-10-01
|
| Series: | Nepal Journal of Dermatology, Venereology & Leprology |
| Subjects: | |
| Online Access: | https://www.nepjol.info/index.php/NJDVL/article/view/67949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227524343595008 |
|---|---|
| author | Alisha Aryal Niraj Bhattarai Ramesh Sharma Poudel Smita Jha Nupendra Shris |
| author_facet | Alisha Aryal Niraj Bhattarai Ramesh Sharma Poudel Smita Jha Nupendra Shris |
| author_sort | Alisha Aryal |
| collection | DOAJ |
| description |
Introduction: Psoriasis is a common skin presentation in dermatology OPD. Methotrexate and apremilast are frequently used for the management of chronic plaque psoriasis.
Objectives: To compare the efficacy and safety of methotrexate versus apremilast for the management of chronic plaque psoriasis
Materials and Methods: This was an interventional study conducted among 41 patients. The patients were divided into 2 groups. Group A received apremilast 10-30mg twice daily, and group B received methotrexate 10-15mg once weekly for 16 weeks. The patients were evaluated at 4, 8 and 16 weeks. PASI score, DLQI score and adverse effects were documented in every follow-up.
Results: The PASI score significantly reduced from 17.22 ± 8.61 (baseline) to 3.90 ± 2.92 (16 weeks) in group A and 18.64 ± 9.02 (baseline) to 5.95 ± 2.89 (16 weeks) in groups B (P = < 0.001). At 16 weeks, the mean PASI score (3.90 ± 2.92) in group A was significantly less than group B (5.95 ± 2.89) (P = 0.02). The percentage reduction of mean PASI from baseline to 16 weeks was 77% in group A and 68.07% in group B. PASI 75 was achieved by 11 patients (52.30 %) in group A and 8 patients (40 %) in group B at 16 weeks. Both groups had a significant decrease in DLQI as compared to baseline at 16 weeks, with insignificant differences between the two groups during each visit. No severe side effects were seen in both groups.
Conclusion: Both treatments can be considered in treating chronic plaque psoriasis. However, apremilast showed more efficacy than methotrexate.
|
| format | Article |
| id | doaj-art-ade08ef167344c7b834f1ba60bc79f7e |
| institution | Kabale University |
| issn | 2091-0231 2091-167X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON) |
| record_format | Article |
| series | Nepal Journal of Dermatology, Venereology & Leprology |
| spelling | doaj-art-ade08ef167344c7b834f1ba60bc79f7e2025-08-23T10:03:32ZengSociety of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON)Nepal Journal of Dermatology, Venereology & Leprology2091-02312091-167X2024-10-0122210.3126/njdvl.v22i2.67949A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional StudyAlisha Aryal0https://orcid.org/0000-0003-1292-9063Niraj Bhattarai1Ramesh Sharma Poudel2Smita Jha3Nupendra Shris4Nepalgunj Medical College, Kohalpur, Banke, NepalSushil Koirala Prakhar Cancer Hospital, Banke, NepalNepalgunj Medical College, Kohalpur, Banke, NepalNepalgunj Medical College, Kohalpur, Banke, NepalNepalgunj Medical College, Kohalpur, Banke, Nepal Introduction: Psoriasis is a common skin presentation in dermatology OPD. Methotrexate and apremilast are frequently used for the management of chronic plaque psoriasis. Objectives: To compare the efficacy and safety of methotrexate versus apremilast for the management of chronic plaque psoriasis Materials and Methods: This was an interventional study conducted among 41 patients. The patients were divided into 2 groups. Group A received apremilast 10-30mg twice daily, and group B received methotrexate 10-15mg once weekly for 16 weeks. The patients were evaluated at 4, 8 and 16 weeks. PASI score, DLQI score and adverse effects were documented in every follow-up. Results: The PASI score significantly reduced from 17.22 ± 8.61 (baseline) to 3.90 ± 2.92 (16 weeks) in group A and 18.64 ± 9.02 (baseline) to 5.95 ± 2.89 (16 weeks) in groups B (P = < 0.001). At 16 weeks, the mean PASI score (3.90 ± 2.92) in group A was significantly less than group B (5.95 ± 2.89) (P = 0.02). The percentage reduction of mean PASI from baseline to 16 weeks was 77% in group A and 68.07% in group B. PASI 75 was achieved by 11 patients (52.30 %) in group A and 8 patients (40 %) in group B at 16 weeks. Both groups had a significant decrease in DLQI as compared to baseline at 16 weeks, with insignificant differences between the two groups during each visit. No severe side effects were seen in both groups. Conclusion: Both treatments can be considered in treating chronic plaque psoriasis. However, apremilast showed more efficacy than methotrexate. https://www.nepjol.info/index.php/NJDVL/article/view/67949ApremilastChronic plaque psoriasisEfficacyMethotrexate |
| spellingShingle | Alisha Aryal Niraj Bhattarai Ramesh Sharma Poudel Smita Jha Nupendra Shris A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study Nepal Journal of Dermatology, Venereology & Leprology Apremilast Chronic plaque psoriasis Efficacy Methotrexate |
| title | A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study |
| title_full | A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study |
| title_fullStr | A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study |
| title_full_unstemmed | A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study |
| title_short | A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study |
| title_sort | comparative study on efficacy and safety of methotrexate versus apremilast in the management of chronic plaque psoriasis tertiary care center based interventional study |
| topic | Apremilast Chronic plaque psoriasis Efficacy Methotrexate |
| url | https://www.nepjol.info/index.php/NJDVL/article/view/67949 |
| work_keys_str_mv | AT alishaaryal acomparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT nirajbhattarai acomparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT rameshsharmapoudel acomparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT smitajha acomparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT nupendrashris acomparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT alishaaryal comparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT nirajbhattarai comparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT rameshsharmapoudel comparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT smitajha comparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy AT nupendrashris comparativestudyonefficacyandsafetyofmethotrexateversusapremilastinthemanagementofchronicplaquepsoriasistertiarycarecenterbasedinterventionalstudy |